Gossamer Bio Inc GOSS

Healthcare Biotechnology

Gossamer Bio, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH). Its product candidate Seralutinib, also known as GB002, is an investigational inhaled, small molecule, platelet-derived growth factor receptor (PDGFR), colony-stimulating factor 1 receptor (CSF1R), and c-KIT inhibitor, being evaluated in a Phase III clinical trial for the treatment of PAH. In contrast to the three classes of marketed vasodilatory therapies for PAH, its seralutinib has the potential to reverse pathological remodeling by addressing mechanisms that underlie PAH. Inhaled seralutinib, which is designed to act on both isoforms of the PDGFR, a and ß, as well as the CSF1R and c-KIT pathways. In addition to PAH, seralutinib holds the potential as a therapeutic option for the treatment of pulmonary hypertension associated with interstitial lung disease (PH-ILD).

NDAQ:GOSS - Post by User

Gossamer Bio Inc

Bullboard Posts

Next >>

Post by coolfooldumbguyon Dec 16, 2019 11:21am

101 Views

Post# 30459327

watching this one for

an entry point,it is really good to be on the sidelines looking at this one getting pounded down in its stock price but at some point it will be a buy for me,so glta.

Bullboard Posts

Next >>

Critical raw materials pioneer drives Europe’s clean energy transition